The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.
 
Or Kalchiem-Dekel
No Relationships to Disclose
 
Christina J. Falcon
No Relationships to Disclose
 
Christine M. Bestvina
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Bristol-Myers Squibb/Celgene; Creative Educational Concepts; Curio Science; CVS; Genentech; Janssen; Jazz Pharmaceuticals; Novartis; OncLive Clinical Congress Consultants; Sanofi/Regeneron; Seagen; Takeda
Speakers' Bureau - Merck
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Dazhi Liu
Consulting or Advisory Role - InVitae
 
Lauren A. Kaplanis
No Relationships to Disclose
 
Clare Wilhelm
No Relationships to Disclose
 
Jordan Eichholz
No Relationships to Disclose
 
Guilherme Harada
Speakers' Bureau - AstraZeneca; MSD; Pfizer
 
Lori J. Wirth
Consulting or Advisory Role - Bayer; Blueprint Medicines; Coherus Biosciences; Eisai; Exelixis; Lilly; Loxo; Merck; Morphic Therapeutic
Research Funding - Ayala Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst)
Expert Testimony - Eisai
Other Relationship - PDS Biotechnology
 
Robert P. Lee
No Relationships to Disclose
 
David Kadosh
No Relationships to Disclose
 
Robin B Mendelsohn
Consulting or Advisory Role - Exact Sciences
Speakers' Bureau - Medscape
 
Jessica Donington
Honoraria - AstraZeneca; BMS; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; BMS; Roche/Genentech
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; ITeos Therapeutics; Jounce Therapeutics; Karyopharm Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV More; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer